2023
Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.
Flaig T, Rosenberg J, Hoimes C, O'Donnell P, Mar N, Gourdin T, Henry S, Bilen M, George S, Barata P, Srinivas S, Rao S, Assikis V, Burgess E, Ramamurthy C, Haas G, Lukas J, Mildiner-Earley S, Yu Y, Petrylak D. Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H. Journal Of Clinical Oncology 2023, 41: 4595-4595. DOI: 10.1200/jco.2023.41.16_suppl.4595.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerEvent-free survivalPhase 1b/2 studyPathological complete responseCancer-related therapyEV treatmentUrothelial cancerSafety profilePD-1/L1 inhibitorsMedian event-free survivalPelvic lymph node dissectionAdvanced urothelial cancerAntitumor activityCisplatin-ineligible patientsManageable safety profileNeoadjuvant treatment optionsOngoing phase 2Pathological downstaging ratePts underwent surgeryTolerable safety profileCentral pathology reviewKey secondary endpointLymph node dissectionPhase 3 studyInvasive bladder cancer
2006
Upregulation of thymidine phosphorylase (TP) by radiation (XRT): Phase II study of capecitabine (CAP) with XRT in pts with locally advanced (LA) pancreatic cancer
Roy S, Russo S, Black G, Eloubeidi M, Steg A, Zelterman D, Johnson M, Diasio R, Saif M. Upregulation of thymidine phosphorylase (TP) by radiation (XRT): Phase II study of capecitabine (CAP) with XRT in pts with locally advanced (LA) pancreatic cancer. Journal Of Clinical Oncology 2006, 24: 14001-14001. DOI: 10.1200/jco.2006.24.18_suppl.14001.Peer-Reviewed Original ResearchPhase II studyLA pancreatic cancerEfficacy of capecitabinePancreatic cancerII studyTNF-alphaThymidine phosphorylaseGI bleedingDose reductionSix-month survival ratesTP/DPD ratioTNF-alpha mRNA levelsPhase IActivity of capecitabineAdvanced pancreatic cancerGrade 1 anemiaGrade 1 thrombocytopeniaNausea/vomitingPts underwent surgeryEffect of XRTConcurrent XRTStable diseaseUnderwent surgeryMedian survivalPartial response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply